

Zarife Sahenk

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8605158/publications.pdf>

Version: 2024-02-01

59
papers

4,174
citations

136950

32
h-index

149698

56
g-index

61
all docs

61
docs citations

61
times ranked

4160
citing authors

#	ARTICLE	IF	CITATIONS
1	AAV1.NT-3 gene therapy for X-linked Charcot-Marie-Tooth neuropathy type 1. <i>Gene Therapy</i> , 2022, 29, 127-137.	4.5	22
2	Systemic delivery of AAVrh74.tMCK.hCAPN3 rescues the phenotype in a mouse model for LGMD2A/R1. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 401-414.	4.1	9
3	Unmet needs and evolving treatment for limb girdle muscular dystrophies. <i>Neurodegenerative Disease Management</i> , 2021, 11, 411-429.	2.2	22
4	AAV1.NT-3 gene therapy in a CMT2D model: phenotypic improvements in <i>GarsP278KY/+</i> mice. <i>Brain Communications</i> , 2021, 3, fcab252.	3.3	15
5	Gene therapy to promote regeneration in Charcot-Marie-Tooth disease. <i>Brain Research</i> , 2020, 1727, 146533.	2.2	21
6	Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy. <i>JAMA Neurology</i> , 2020, 77, 1122.	9.0	226
7	Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy. <i>Medicine (United States)</i> , 2019, 98, e15858.	1.0	61
8	A Novel De Novo Heterozygous SCN4a Mutation Causing Congenital Myopathy, Myotonia and Multiple Congenital Anomalies. <i>Journal of Neuromuscular Diseases</i> , 2019, 6, 467-473.	2.6	9
9	Gene Delivery for Limb-Girdle Muscular Dystrophy Type 2D by Isolated Limb Infusion. <i>Human Gene Therapy</i> , 2019, 30, 794-801.	2.7	34
10	PUMILIO hyperactivity drives premature aging of Norad-deficient mice. <i>ELife</i> , 2019, 8, .	6.0	65
11	Autoantibodies Targeting Components of Sarcolemma Repair Represent a Pathogenic Mechanism in Idiopathic Immune Myopathies. <i>FASEB Journal</i> , 2019, 33, 701.2.	0.5	0
12	Pre-clinical Safety and Off-Target Studies to Support Translation of AAV-Mediated RNAi Therapy for FSHD. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 121-130.	4.1	44
13	AAV1.NT-3 gene therapy increases muscle fiber diameter through activation of mTOR pathway and metabolic remodeling in a CMT mouse model. <i>Gene Therapy</i> , 2018, 25, 129-138.	4.5	40
14	Efficacy of exogenous pyruvate in Trembler ^J mouse model of Charcot-Marie-Tooth neuropathy. <i>Brain and Behavior</i> , 2018, 8, e01118.	2.2	12
15	Eteplirsen treatment for Duchenne muscular dystrophy. <i>Neurology</i> , 2018, 90, e2146-e2154.	1.1	175
16	Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes. <i>Molecular Therapy</i> , 2017, 25, 870-879.	8.2	84
17	A novel p.T139M mutation in HSPB1 highlighting the phenotypic spectrum in a family. <i>Brain and Behavior</i> , 2017, 7, e00774.	2.2	12
18	Clinical trials of exon skipping in Duchenne muscular dystrophy. <i>Expert Opinion on Orphan Drugs</i> , 2017, 5, 683-690.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Impaired regeneration in calpain-3 null muscle is associated with perturbations in mTORC1 signaling and defective mitochondrial biogenesis. <i>Skeletal Muscle</i> , 2017, 7, 27.	4.2	29
20	Defective membrane fusion and repair in <i>Anoctamin5</i> -deficient muscular dystrophy. <i>Human Molecular Genetics</i> , 2016, 25, 1900-1911.	2.9	88
21	AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 256-270.	3.7	78
22	Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 185-192.	2.6	34
23	A slowly progressive form of limb-girdle muscular dystrophy type 2C associated with founder mutation in the <i>SCCG</i> gene in Puerto Rican Hispanics. <i>Molecular Genetics & Genomic Medicine</i> , 2015, 3, 92-98.	1.2	10
24	A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy. <i>Molecular Therapy</i> , 2015, 23, 192-201.	8.2	193
25	AAV1.NT-3 Gene Therapy for Charcot-Marie-Tooth Neuropathy. <i>Molecular Therapy</i> , 2014, 22, 511-521.	8.2	86
26	VIP-expressing Dendritic Cells Protect Against Spontaneous Autoimmune Peripheral Polyneuropathy. <i>Molecular Therapy</i> , 2014, 22, 1353-1363.	8.2	13
27	Vascular Delivery of rAAVrh74.MCK.GALGT2 to the Gastrocnemius Muscle of the Rhesus Macaque Stimulates the Expression of Dystrophin and Laminin α 2 Surrogates. <i>Molecular Therapy</i> , 2014, 22, 713-724.	8.2	61
28	Impaired regeneration in LGMD2A supported by increased PAX7-positive satellite cell content and muscle-specific microrna dysregulation. <i>Muscle and Nerve</i> , 2013, 47, 731-739.	2.2	21
29	Update on the Treatment of Duchenne Muscular Dystrophy. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 332.	4.2	52
30	Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. <i>Human Molecular Genetics</i> , 2013, 22, 4929-4937.	2.9	53
31	Pathogenesis of Autosomal Dominant Hereditary Spastic Paraplegia (SPG6) Revealed by a Rat Model. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1016-1028.	1.7	17
32	Mutant HSPB1 overexpression in neurons is sufficient to cause age-related motor neuronopathy in mice. <i>Neurobiology of Disease</i> , 2012, 47, 163-173.	4.4	35
33	The Muscular Dystrophies: Distinct Pathogenic Mechanisms Invite Novel Therapeutic Approaches. <i>Current Rheumatology Reports</i> , 2011, 13, 199-207.	4.7	14
34	Gentamicin-induced readthrough of stop codons in duchenne muscular dystrophy. <i>Annals of Neurology</i> , 2010, 67, 771-780.	5.3	238
35	Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. <i>Annals of Neurology</i> , 2010, 68, 629-638.	5.3	214
36	Dystrophin Immunity in Duchenne's Muscular Dystrophy. <i>New England Journal of Medicine</i> , 2010, 363, 1429-1437.	27.0	546

#	ARTICLE	IF	CITATIONS
37	TrkB and TrkC agonist antibodies improve function, electrophysiologic and pathologic features in TremblerJ mice. <i>Experimental Neurology</i> , 2010, 224, 495-506.	4.1	31
38	Overexpression of <i>Galgt2</i> in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice. <i>American Journal of Physiology - Cell Physiology</i> , 2009, 296, C476-C488.	4.6	78
39	Neurotrophin-3 deficient Schwann cells impair nerve regeneration. <i>Experimental Neurology</i> , 2008, 212, 552-556.	4.1	26
40	Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 4318-4322.	7.1	235
41	Pilot Clinical Trial of NT-3 in CMT1A Patients. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2007, 2, 97-108.	0.0	7
42	Neurotrophins and Peripheral Neuropathies. <i>Brain Pathology</i> , 2006, 16, 311-319.	4.1	13
43	Evidence for impaired axonal regeneration in PMP22 duplication: studies in nerve xenografts. <i>Journal of the Peripheral Nervous System</i> , 2003, 8, 116-127.	3.1	16
44	Pathogenesis of X-Linked Charcot-Marie-Tooth Disease: Differential Effects of Two Mutations in Connexin 32. <i>Journal of Neuroscience</i> , 2003, 23, 10548-10558.	3.6	53
45	Intracellular Processing and Toxicity of the Truncated Androgen Receptor: Nuclear Congophilia-Associated Cell Death. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 652-663.	1.7	1
46	Abnormal Schwann Cell-Axon Interactions in CMT Neuropathies: The Effects of Mutant Schwann Cells on the Axonal Cytoskeleton and Regeneration-Associated Myelination. <i>Annals of the New York Academy of Sciences</i> , 1999, 883, 415-426.	3.8	37
47	Alterations in Nodes of Ranvier and Schmidt-Lanterman Incisures in Charcot-Marie-Tooth Neuropathies. <i>Annals of the New York Academy of Sciences</i> , 1999, 883, 508-512.	3.8	7
48	Effects of PMP22 duplication and deletions on the axonal cytoskeleton. <i>Annals of Neurology</i> , 1999, 45, 16-24.	5.3	93
49	Novel single base polymorphisms and rare sequence variants in the laminin α 2-chain coding region detected by RNA/SSCP analysis. <i>Human Mutation</i> , 1999, 13, 174-174.	2.5	0
50	Abnormalities in the axonal cytoskeleton induced by a connexin32 mutation in nerve xenografts. , 1998, 51, 174-184.		67
51	A novel <i>PMP22</i> point mutation causing HNPP phenotype. <i>Neurology</i> , 1998, 51, 702-707.	1.1	41
52	Fate of Schwann Cells in CMT1A and HNPP: Evidence for Apoptosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 635-642.	1.7	34
53	Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy. <i>New England Journal of Medicine</i> , 1995, 333, 832-838.	27.0	489
54	Gene delivery to spinal motor neurons. <i>Brain Research</i> , 1993, 606, 126-129.	2.2	25

#	ARTICLE	IF	CITATIONS
55	Alterations in slow transport kinetics induced by estramustine phosphate, an agent binding to microtubule-associated proteins. <i>Journal of Neuroscience Research</i> , 1992, 32, 481-493.	2.9	12
56	Studies on the pathogenesis of vincristine-induced neuropathy. <i>Muscle and Nerve</i> , 1987, 10, 80-84.	2.2	105
57	Axonal tubulin and microtubules: Morphologic evidence for stable regions on axonal microtubules. <i>Cytoskeleton</i> , 1987, 8, 155-164.	4.4	55
58	Axoplasmic transport in zinc pyridinethione neuropathy: Evidence for an abnormality in distal turn-around. <i>Brain Research</i> , 1980, 186, 343-353.	2.2	57
59	Ultrastructural Study of Zinc Pyridinethione-Induced Peripheral Neuropathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 1979, 38, 532-550.	1.7	45